The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.

Launched by CAIRO UNIVERSITY · May 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment option for people suffering from chronic pain caused by post-herpetic neuralgia, which is a condition that can occur after a shingles infection. The researchers want to see if using a specific type of nerve block, called an Erector Spinae Block, along with a medication called Betamethasone, can help manage this pain better than standard treatments alone.

To participate in this trial, you need to be between the ages of 18 and 75 and have been diagnosed with chronic pain that has lasted for more than three months since your shingles rash appeared. You should also be in generally good health, with no severe liver or kidney issues, and not be taking long-term opioids or blood thinners. If you join the study, you’ll receive the new treatment and be monitored closely to see how well it works for you. This trial is currently looking for participants, and it could be an opportunity to help improve pain management for yourself and others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients age between 18 and 75.
• • Patients with American Society of Anesthesiologists (ASA) II and III status.
• • Patients diagnosed with truncal chronic post herpetic neuralgia( neuropathic pain persistent for more than 3 months from the onset of rash appearance )
• Exclusion Criteria:
• • Patients unable to comprehend the informed consent.
• • Patients on long term opioid regimens.
• • Patients with impairment in hepatic (Alanine aminotransferase (ALT) \>50 U/L, and/or Aspartate aminotransferase (AST): \>45 U/L) or renal functions( creatinine level ≥1.5 mg/dL)
• • Patients on anti-coagulation regimens.
• • Patients with coagulation abnormalities (i.e. international normalized ratio (INR) ≥1.5 and/or platelets ≤50000)
• • Local infection in the site of the block.
• • Patients with body mass index (BMI) \> 35.